Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib-Reference-Cited by-同舟云学术

Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib

Published:2022-03-01 Issue:3 Volume:45 Page:333-338
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Ikesue Hiroaki¹,Yamamoto Haruna¹,Hirabatake Masaki¹,Hashida Tohru¹,Chung Hobyung²,Inokuma Tetsuro²,Muroi Nobuyuki¹

Affiliation:

1. Department of Pharmacy, Kobe City Medical Center General Hospital

2. Department of Gastroenterology and Hepatology, Kobe City Medical Center General Hospital

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/45/3/45_b21-00913/_pdf

Reference29 articles.

1. 1) Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int. J. Cancer, 149, 778–789 (2021).

2. 2) Cancer Information Service NCC. Japan. “Cancer Registry and Statistics.”: ‹http://ganjoho.jp/reg_stat/statistics/dl/index.html›, accessed 20 September, 2021.

3. 3) Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391, 1163–1173 (2018).

4. 4) Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J. Gastroenterol., 52, 512–519 (2017).

5. 5) Shimamura Y, Abe K, Maeda T, Matsui T, Ishiguro A, Takizawa H. Association between renal adverse effects and mortality in patients with hepatocellular carcinoma treated with lenvatinib. In Vivo, 35, 1647–1653 (2021).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment;Scientific Reports;2024-03-02

2. Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab;Cancer Chemotherapy and Pharmacology;2024-02-25

3. Pharmacist–Urologist Collaborative Management for Patients with Renal Cell Carcinoma Receiving Pazopanib Monotherapy;Biological and Pharmaceutical Bulletin;2023-08-01

4. Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study;Medicina Oral Patología Oral y Cirugia Bucal;2020